Literature DB >> 9863603

The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease.

P G Kehoe1, H Williams, P Holmans, G Wilcock, N J Cairns, J Neal, M J Owen.   

Abstract

Previous work has shown an association between the K variant of the butyrylcholinesterase (BCHE) gene and Alzheimer's disease (AD) in patients carrying the epsilon4 allele of ApoE. We attempted to replicate this finding in 181 UK white AD cases and 71 controls. No difference was found in BCHE-K genotypes (p=0.75) or alleles (p=0.70) between patients and controls. Moreover, despite a significant excess of ApoE epsilon4 in patients versus controls (p<0.0001), we found no evidence to support previous reports of an interaction between ApoE and BCHE-K (chi2=1.49, df=4, p=0.83).

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9863603      PMCID： PMC1051518          DOI： 10.1136/jmg.35.12.1034

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


  15 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

Review 3.  Association studies in psychiatric genetics.

Authors:  M J Owen; P Holmans; P McGuffin
Journal:  Mol Psychiatry       Date:  1997-07       Impact factor: 15.992

Review 4.  Amyloid, the presenilins and Alzheimer's disease.

Authors:  J Hardy
Journal:  Trends Neurosci       Date:  1997-04       Impact factor: 13.837

5.  Recognition of two new phenotypes segregating the E1k allele for plasma cholinesterase.

Authors:  M Whittaker; J J Britten
Journal:  Hum Hered       Date:  1988       Impact factor: 0.444

6.  No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease.

Authors:  A B Singleton; G Smith; A M Gibson; R Woodward; R H Perry; P G Ince; J A Edwardson; C M Morris
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

7.  Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site.

Authors:  F S Jensen; L R Nielsen; M Schwartz
Journal:  Hum Hered       Date:  1996 Jan-Feb       Impact factor: 0.444

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  Apolipoprotein E and Alzheimer disease.

Authors:  W J Strittmatter; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205
View more
  8 in total

Review 1.  Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

Authors:  E Giacobini
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

3.  Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

Authors:  K M Mattila; J O Rinne; M Röyttä; P Laippala; T Pietilä; H Kalimo; T Koivula; H Frey; T Lehtimäki
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

4.  Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.

Authors:  S P McIlroy; V L Crawford; K B Dynan; B M McGleenon; M D Vahidassr; J T Lawson; A P Passmore
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

5.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

6.  Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection?

Authors:  Gumpeny Ramachandra Sridhar; Hanuman Thota; Appa Rao Allam; Changalasetty Suresh Babu; Akula Siva Prasad; Ch Divakar
Journal:  Lipids Health Dis       Date:  2006-11-11       Impact factor: 3.876

7.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16

8.  Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.

Authors:  Per Johansson; Erik G Almqvist; Jan-Ove Johansson; Niklas Mattsson; Ulf Andreasson; Oskar Hansson; Anders Wallin; Kaj Blennow; Henrik Zetterberg; Johan Svensson
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.